We have updated our report on psoriasis treatments in clinical trials and development and announced today that a record SEVENTY potential new treatments for psoriasis and psoriatic arthritis are in development by the biotech and pharmaceutical industries.
This is an extraordinary statistic, particularly for anyone who had psoriasis in the 1970s or 1980s, when developments were few and far between. This strong foundation of treatments in the pipeline suggests that the explosive growth in new treatment options over the last several years may continue in the years to come. And it means down the road, more psoriasis patients are likely to find a treatment that brings them relief, if not a remedy.
The treatments being studied run the gamut, from medications that treat symptoms to topicals and injectibles that address the underlying immune system cause (or causes). They are being studied by little start-ups and national and international pharmaceutical giants. (A few are even being studied by universities.)
Will they all pan out? Nope. But we’re grateful that these companies are taking that financial risk. And picture this: one day, those treatments that successfully run the clinical testing gauntlet may receive FDA approval and become available to the psoriasis community.
For more on this new report, you can read the news release: New report from Psoriasis Cure Now shows biotechs studying a record 70 psoriasis treatments.
Or if you want to go right to the list, click here: Hope: Psoriasis and Psoriatic Arthritis Drugs in Clinical Trials.
Category: Uncategorized
